HeartBeam Reports First-Quarter 2026 Results, Advances Commercial Launch with Partnerships and $11.5M Offering

HeartBeam Inc. (NASDAQ: BEAT) has reported its first-quarter 2026 operational and financial results, underscoring key advances in its commercial launch and continued development of its cardiac monitoring platform. The company disclosed the initiation of commercial partnerships in major U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and a public offering that raised $11.5 million in gross proceeds during April.

For the first quarter, HeartBeam recorded a net loss of $4.7 million, an improvement from the $5.5 million net loss in the prior-year period. Research and development expenses decreased year over year as the company shifted focus toward commercialization of its FDA-cleared cardiac monitoring system. The company's platform, which received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG.

HeartBeam's technology aims to enable portable devices that can be used outside medical facilities, allowing physicians to identify cardiac health trends and acute conditions while directing patients to appropriate care. The company holds over 20 issued patents related to its technology. Details on the cleared indications for use are available at https://www.heartbeam.com/indications.

The $11.5 million public offering completed in April provides additional capital to support the company's commercial rollout and growth initiatives. The first-quarter results reflect the company's strategic pivot from development to market entry, with partnerships established in key U.S. markets to distribute its cable-free, 3D ECG device. The ambulatory ECG patch initiative is also progressing, aiming to expand the platform's application for continuous monitoring.

Investors can access the full press release at https://ibn.fm/guMCF and stay updated on the latest news at https://ibn.fm/BEAT. HeartBeam's technology represents a potential shift in cardiac care by enabling remote, comprehensive ECG monitoring that could reduce the need for in-clinic visits and improve early detection of heart conditions.